Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 72.47 Million USD | -25.26% |
| 2022 | 96.96 Million USD | 568.85% |
| 2021 | 14.49 Million USD | -86.65% |
| 2020 | 108.62 Million USD | 758.05% |
| 2019 | 12.65 Million USD | -53.74% |
| 2018 | 27.36 Million USD | 1838.07% |
| 2017 | 1.41 Million USD | 56.51% |
| 2016 | 902.19 Thousand USD | -94.47% |
| 2015 | 16.3 Million USD | 39.95% |
| 2014 | 11.65 Million USD | 212.1% |
| 2013 | 3.73 Million USD | 5.87% |
| 2012 | 3.52 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 74.24 Million USD | 2.45% |
| 2024 Q2 | 73.17 Million USD | -1.43% |
| 2023 FY | 72.47 Million USD | -25.26% |
| 2023 Q2 | 69.73 Million USD | -15.4% |
| 2023 Q3 | 67.88 Million USD | -2.66% |
| 2023 Q4 | 72.47 Million USD | 6.76% |
| 2023 Q1 | 82.43 Million USD | -14.98% |
| 2022 Q4 | 96.96 Million USD | -19.42% |
| 2022 Q2 | 269.46 Million USD | 65.65% |
| 2022 Q1 | 162.67 Million USD | 1022.1% |
| 2022 FY | 96.96 Million USD | 568.85% |
| 2022 Q3 | 120.32 Million USD | -55.35% |
| 2021 Q2 | 99.78 Million USD | -6.83% |
| 2021 Q1 | 107.1 Million USD | -1.4% |
| 2021 Q3 | 126.25 Million USD | 26.53% |
| 2021 Q4 | 14.49 Million USD | -88.52% |
| 2021 FY | 14.49 Million USD | -86.65% |
| 2020 FY | 108.62 Million USD | 758.05% |
| 2020 Q3 | 72.11 Million USD | 8.42% |
| 2020 Q4 | 108.62 Million USD | 50.62% |
| 2020 Q2 | 66.51 Million USD | 354.85% |
| 2020 Q1 | 14.62 Million USD | 15.52% |
| 2019 Q4 | 12.65 Million USD | -15.12% |
| 2019 Q2 | 18.62 Million USD | -41.96% |
| 2019 Q1 | 32.08 Million USD | 17.24% |
| 2019 FY | 12.65 Million USD | -53.74% |
| 2019 Q3 | 14.91 Million USD | -19.92% |
| 2018 Q2 | 20.91 Million USD | -23.36% |
| 2018 Q3 | 25.09 Million USD | 19.99% |
| 2018 Q4 | 27.36 Million USD | 9.07% |
| 2018 FY | 27.36 Million USD | 1838.07% |
| 2018 Q1 | 27.28 Million USD | 1832.27% |
| 2017 FY | 1.41 Million USD | 56.51% |
| 2017 Q4 | 1.41 Million USD | 1.12% |
| 2017 Q3 | 1.39 Million USD | -17.9% |
| 2017 Q2 | 1.7 Million USD | 0.19% |
| 2017 Q1 | 1.69 Million USD | 88.18% |
| 2016 FY | 902.19 Thousand USD | -94.47% |
| 2016 Q1 | 7.02 Million USD | -56.89% |
| 2016 Q4 | 902.19 Thousand USD | -36.99% |
| 2016 Q3 | 1.43 Million USD | -78.11% |
| 2016 Q2 | 6.54 Million USD | -6.93% |
| 2015 Q1 | 13.27 Million USD | 13.95% |
| 2015 Q3 | 19.93 Million USD | 36.49% |
| 2015 Q4 | 16.3 Million USD | -18.22% |
| 2015 FY | 16.3 Million USD | 39.95% |
| 2015 Q2 | 14.6 Million USD | 10.03% |
| 2014 Q3 | 5.66 Million USD | 0.0% |
| 2014 FY | 11.65 Million USD | 212.1% |
| 2014 Q4 | 11.65 Million USD | 105.81% |
| 2013 FY | 3.73 Million USD | 5.87% |
| 2013 Q4 | 3.73 Million USD | 0.0% |
| 2012 FY | 3.52 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -264074.534% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -665.599% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -8860.378% |
| Rebus Holdings, Inc. | 5.24 Million USD | -1282.507% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -22.803% |
| Qrons Inc. | 1.48 Million USD | -4768.03% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -5810.148% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 3.269% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -162042.026% |
| Skye Bioscience, Inc. | 14.07 Million USD | -414.993% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -35.955% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -656.323% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -17090.821% |
| SQZ Biotechnologies Company | 50.03 Million USD | -44.829% |
| Intellipharmaceutics International Inc. | 12 Million USD | -503.484% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1781.668% |
| Mesoblast Limited | 188.44 Million USD | 61.543% |
| Marizyme, Inc. | 26.67 Million USD | -171.674% |
| Genus plc | 485 Million USD | 85.058% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1140.385% |
| Pharming Group N.V. | 244.07 Million USD | 70.308% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -3505.289% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -2780.03% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1807.132% |
| ContraFect Corporation | 32.53 Million USD | -122.775% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -3557.735% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1793.356% |
| IMV Inc. | 37.93 Million USD | -91.051% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -515.298% |
| MultiCell Technologies, Inc. | 1617.67 USD | -4479861.921% |
| ONE Bio Corp. | 27.49 Million USD | -163.571% |
| Accustem Sciences Inc. | 1.07 Million USD | -6615.009% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 6.389% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -3326.413% |
| Q BioMed Inc. | 8.13 Million USD | -791.08% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 12.617% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1308.288% |
| Biomind Labs Inc. | 1.49 Million USD | -4735.875% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 38.958% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -701.476% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -293.791% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -4954.256% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -50901.795% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -35934.428% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1161.282% |
| GB Sciences, Inc. | 5.41 Million USD | -1237.706% |
| Alpha Cognition Inc. | 7.16 Million USD | -911.49% |
| HST Global, Inc. | 593.59 Thousand USD | -12108.87% |
| CSL Limited | 18.62 Billion USD | 99.611% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -5655.353% |
| Halberd Corporation | 728.71 Thousand USD | -9844.986% |
| Enzolytics Inc. | 365.26 Million USD | 80.16% |
| Agentix Corp. | 2.51 Million USD | -2786.653% |
| Resverlogix Corp. | 67.39 Million USD | -7.53% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -8540.543% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 83.713% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -4128.18% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -192.859% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -508.841% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1877.292% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1714.613% |
| Zenith Capital Corp. | 27.56 Thousand USD | -262771.341% |
| Genscript Biotech Corporation | 1.32 Billion USD | 94.534% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -30266.556% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1840.682% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -10544.445% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -2572.588% |
| Kadimastem Ltd | 3.5 Million USD | -1967.725% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -108180.417% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -44.181% |
| BioStem Technologies, Inc. | 15.9 Million USD | -355.659% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -15495.256% |
| LadRx Corporation | 2.2 Million USD | -3193.346% |
| Cell Source, Inc. | 15.8 Million USD | -358.482% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1227.887% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1227.887% |
| NovAccess Global Inc. | 7.86 Million USD | -821.937% |
| Affymax, Inc. | 8.87 Million USD | -716.943% |
| Itoco Inc. | 1.65 Million USD | -4283.81% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3432.474% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1098.066% |
| Mobile Lads Corp. | 1.31 Million USD | -5417.409% |
| CytoDyn Inc. | 127.89 Million USD | 43.335% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -173279.746% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -4526.664% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -556.126% |
| SYBLEU INC | 681.41 Thousand USD | -10535.4% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1087.678% |
| International Stem Cell Corporation | 5.27 Million USD | -1273.337% |
| Bioxytran, Inc. | 3.24 Million USD | -2130.22% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -11480.37% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1469.613% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -76.776% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -225.493% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -3478.131% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -1222.946% |
| Neutra Corp. | 973.52 Thousand USD | -7344.154% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -149.771% |
| PureTech Health plc | 125.58 Million USD | 42.292% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1828.895% |
| IXICO plc | 1.9 Million USD | -3713.677% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -253.018% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 29.86% |
| CSL Limited | 18.62 Billion USD | 99.611% |
| Cellectis S.A. | 249.36 Million USD | 70.938% |